The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.

A groundbreaking study recently published in the New England Journal of Medicine has shown that a combination of two existing ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in ...

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an ...

China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...